This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| T13 | |
|---|---|
| Name | T13 |
| Synonyms | Patau syndrome |
| Field | Genetics, Pediatrics, Obstetrics |
| Onset | Congenital |
| Causes | Chromosomal trisomy |
| Prognosis | Variable; often severe |
T13 is a chromosomal aneuploidy characterized by the presence of an extra copy of chromosome 13, commonly known as Patau syndrome. It produces multisystem developmental anomalies affecting craniofacial structures, cardiac formation, neurological development, and limb morphogenesis, with significant impacts on perinatal survival and long-term morbidity. Recognition involves prenatal screening and postnatal cytogenetic confirmation; management is multidisciplinary and increasingly individualized through ethical decision-making and evolving surgical, medical, and supportive interventions.
The condition is defined cytogenetically by full trisomy, mosaicism, or structural rearrangements involving chromosome 13, historically labeled Patau syndrome after Klaus Patau who described multiple cases. Alternate nomenclature appears in clinical genetics texts and institutional databases such as American College of Medical Genetics and Genomics reports and World Health Organization classification schemes. Phenotypic descriptors include craniofacial dysmorphism, polydactyly, holoprosencephaly spectrum, and congenital heart defects, terms used in consensus statements from bodies like Society for Maternal-Fetal Medicine and position papers from Royal College of Obstetricians and Gynaecologists.
The etiology is typically nondisjunction during meiosis producing full trisomy 13; other mechanisms include Robertsonian translocation involving chromosome 13 and mosaic postzygotic errors documented in cytogenetic surveys. Key genetic references include karyotype analyses published by groups at National Institutes of Health, University of Cambridge cytogenetics laboratories, and population registries such as European Network on Congenital Anomalies. Molecular studies have mapped dosage-sensitive loci on chromosome 13 implicated in midline patterning and cardiac morphogenesis, with investigations from laboratories at Harvard Medical School, Stanford University School of Medicine, and Max Planck Institute addressing gene expression perturbations. Comparative genomic hybridization and microarray data from consortia including DECIPHER and ClinGen further delineate copy-number variation effects. Mosaic cases described in case series from Mayo Clinic and Cleveland Clinic illustrate genotype–phenotype correlation challenges, while prenatal cell-free DNA screening performance has been evaluated by groups at Johns Hopkins University and commercial labs such as Illumina.
Clinical presentation ranges from severe neonatal manifestations—microphthalmia, cleft lip and palate, scalp defects—to less severe mosaic phenotypes. Cardiac lesions commonly include ventricular septal defects and patent ductus arteriosus, reported in surgical series from Great Ormond Street Hospital and Children's Hospital of Philadelphia. Diagnostic pathways follow prenatal ultrasound markers, noninvasive prenatal testing validated in studies at Karolinska Institutet and confirmatory karyotyping or chromosomal microarray from amniocentesis or chorionic villus sampling protocols endorsed by American College of Obstetricians and Gynecologists. Postnatal diagnosis integrates clinical dysmorphology assessment by teams at Boston Children's Hospital and cytogenetic confirmation at reference labs like Molecular Genetics Laboratory, University of British Columbia.
Birth prevalence estimates derive from registry analyses in United States, United Kingdom, Denmark, and Japan, with incidence influenced by maternal age effects studied in cohorts at National University of Ireland and demographic surveillance by Centers for Disease Control and Prevention. Survival statistics from population-based studies in Sweden and longitudinal follow-up at Toronto SickKids Hospital show high neonatal mortality but variable midterm survival among mosaic or surgically treated individuals. Prognostic factors include karyotype type, severity of cardiac and neurological malformations, and access to tertiary care documented in outcome reports from King's College Hospital and multicenter registries coordinated by International Clearinghouse for Birth Defects Surveillance and Research.
Care is multidisciplinary, involving neonatology, pediatric cardiology, craniofacial surgery, neurosurgery, palliative care, and genetics teams as organized in centers like Great Ormond Street Hospital, Boston Children's Hospital, and Royal Children's Hospital Melbourne. Initial stabilization follows neonatal intensive care protocols from Neonatal Resuscitation Program curricula and surgical correction of amenable anomalies is described in case series by European Pediatric Cardiac Surgery Consortium. Ethical frameworks guiding intervention intensity reference guidance from American Academy of Pediatrics and consensus statements from European Society of Paediatric and Neonatal Intensive Care. Supportive measures include feeding interventions by teams at Holland Bloorview Kids Rehabilitation Hospital and developmental therapies coordinated through regional networks such as Early Intervention programs.
Research priorities include natural history studies, genotype–phenotype mapping, and evaluation of neonatal surgical outcomes pursued by consortia at Children's Hospital of Philadelphia, Stanford Medicine, and Vanderbilt University Medical Center. Investigational approaches explore targeted molecular therapies informed by transcriptomic profiling from groups at Broad Institute and developmental biology models in laboratories at University of California, San Francisco and Cold Spring Harbor Laboratory. Prenatal diagnosis and counseling innovations are advanced by Prenatal Diagnosis Journal collaborations and trials of care pathways led by National Perinatal Epidemiology Unit. Bioethical research from Nuffield Council on Bioethics and health-services analyses by Institute for Health Metrics and Evaluation examine outcomes, resource allocation, and family-centered decision-making frameworks.
Category:Chromosomal anomalies